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Long-term effectivenessOutcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in
patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated pa-
tients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data
from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular
filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) aswell as time to and ages at a compos-
ite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a
median of ~ 5 years. Comparedwith no treatment, patients treatedwith agalsidase alfa demonstrated slower de-
cline in renal function and slower progression of left ventricular hypertrophy. Treated male patients with base-
line eGFR b60 mL/min/1.73 m2 had a mean (standard error of the mean [SEM]) annualized change in eGFR of
−2.86 (0.53) mL/min/1.73 m2/y compared with −6.8 (1.5) in the published untreated cohort. The mean
(SEM) rate of LVMI increase with treatment was 0.33 (0.10) g/m2.7/y in males and 0.48 (0.09) in females, com-
paredwith 4.07 (1.03) in untreatedmales and 2.31 (0.81) in untreated females.Morbidity occurred later in treat-
ed patients, with ~16% risk of a composite morbidity event (26% inmales) after 24monthswith ERT versus ~45%
without treatment, with first events and deaths also occurring at older ages in patients administered ERT
(e.g., estimated median survival in treated males was 77.5 years versus 60 years in untreated males). Findings
from these retrospective comparisons of observational data and published literature support the long-term ben-
efits of ERT with agalsidase alfa for Fabry disease in slowing the progression of renal impairment and cardiomy-
opathy. Treatment also appeared to delay the onset of morbidity and mortality. Interpretation of these findings
should take into account that they are based on retrospective comparisons with previously published data.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fabry disease (OMIM 301500) is a rare inherited X-linked
glycosphingolipid storage disorder in which mutations in the α-galac-
tosidase A gene result in functional deficiency of the lysosomalhibitor; ARB, Angiotensin recep-
rular filtration rate; ERT, Enzyme
t ventricular hypertrophy; LVMI,
ion of Diet in Renal Disease; SE,
iversity Medical Centre, J.G.
many.
M. Beck).
. This is an open access article underenzyme α-galactosidase (EC 3.2.1.22) [1]. This leads to progressive ac-
cumulation of glycosphingolipids, particularly globotriaosylceramide,
in almost all tissues and organs. The most serious complications in
adult patients are progressive renal impairment, cardiomyopathy, and
cerebrovascular events, all of which lead to significant morbidity and
mortality and reduced life expectancy [2–8].
Enzyme replacement therapy (ERT) for Fabry disease has been
available for N10 years [9–13]. Currently, it is the only approved
approach to disease modification, and patients are likely to be on
long-term treatment. The international Fabry Outcome Survey (FOS),
sponsored by Shire (Lexington, MA, USA), was initiated in 2001 to col-
lect long-term clinical and safety outcomes data for individuals with
confirmed diagnosis of Fabry disease who either receive agalsidasethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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study of many aspects of Fabry disease and the effects of ERT, including
renal and cardiac outcomes [2,11,15–19].
A past limitation of FOS has been the lack of a robust comparable
untreated cohort. The untreated population in FOS is generally less
severely affected than patients receiving treatment and includes a
higher proportion of females. Untreated patients also have tended
to undergo fewer follow-up assessments and therefore have less out-
come data available [11]. An exploratory analysis suggested that
b 10% of FOS participants could be matched for comparison. Long-
term data on mortality, morbidity, and progression of renal impair-
ment and cardiac disease without ERT are, however, available from
other published studies [8,20].
The objective of our analysis was to compare the long-term renal
and cardiac consequences and morbidity and mortality outcomes for
agalsidase alfa–treated patients from FOS with well-described cohorts
of untreated individuals from previously published studies.2. Methods
2.1. Patients
Patients included in FOS are either receiving agalsidase alfa
(Replagal®; Shire, Lexington, MA, USA) at the approved dosage or are
not receiving any ERT. Details of data collection have been presented
elsewhere [11,14,15,19]. Patients who had been treated with anoth-
er ERT before FOS entry were excluded from this analysis. Patients
who left FOS to be treated with another ERT were censored from
the analyses from the date of leaving. For this analysis, FOS data
were extracted for the period from database inception in 2001
through November 2012. FOS has been approved by the ethics insti-
tutional review boards of participating centers. All participants gave
written informed consent.Morbidity Outcomes Renal Ou
FOS Evaluable Treated
Morbidity Cohort
 (eGFR <80 mL/min)
(n = 79: 38 M, 41 F)
Untreated:
Banikazemi et al. [20]
Placebo Group
(n = 31: 27 M, 4 F)
Untreated: Schiffm
(n = 395: 243
FOS Evaluab
Renal C




(N = 677: 360
Fig. 1. Disposition of agalsidase alfa–treated patients. The All Treated cohort of FOS was subdiv
Morbidity (andmortality), Renal, and Cardiac cohorts for comparisonwith untreated patients (
et al. [21]. eGFR, estimated glomerular filtration rate; F, female; FOS, Fabry Outcome Survey; LVData for untreated patients were derived from three published
sources (Fig. 1) [8,20,21]. Mortality, morbidity, and the progression of
renal impairment were explored in a multinational Fabry disease retro-
spective chart study by Schiffmann et al. [21]. Cardiac changes over time
were examined in a two-center prospective, cross-sectional, longitudi-
nal study by Kampmann et al. [8]. Time from baseline to onset of first
clinical event (e.g., death, cardiac, renal, or cerebrovascular) was
evaluated in a multinational randomized clinical trial of agalsidase
beta versus placebo by Banikazemi et al.; the placebo arm of this study
was used as an untreated comparator cohort [20].
Five different patient populations from FOS were defined to provide
comparator populations that were as closely matched as possible to the
published untreated cohorts (Fig. 1). The All Treated cohort comprised
all patients (children and adults) from FOS who started agalsidase alfa
either before or during FOS entry. The Evaluable Treated cohort, a subset
of the All Treated cohort, excluded patients who had undergone renal
transplant or renal dialysis prior to treatment. Three further subsets of
the Evaluable Treated cohort were also defined. The Evaluable Treated
Morbidity cohort for comparison with data from Banikazemi et al. [20]
comprised adult patients who had a baseline estimated glomerular
filtration rate (eGFR) b80 mL/min/1.73 m2 at treatment start. The
Evaluable Treated Renal cohort for comparison with untreated patients
from Schiffmann et al. [21] included those adults who had ≥3 eGFR
Modification of Diet in Renal Disease (MDRD) values, including at base-
line and 2 years. An Evaluable Treated Cardiac cohort for evaluation
against data from Kampmann et al. [8] included patients with ≥3 left
ventricular mass indexed to height (LVMI) measurements, including
at baseline and 2 years.
2.2. Outcomes analyzed
The rate of change in renal functionwas evaluated as the annualized
change in eGFR in adults (aged ≥18 years), using a four-variable MDRD
eGFR equation [22]. Cardiomyopathy was similarly determinedMissing date for start of treatment (n = 26)
Renal transplant or dialysis (n = 37)
Excluded due to:
Cardiac Outcomestcomes
Morbidity and Mortality Outcomes
ann et al. [21]
 M, 152 F)
Untreated: Kampmann et al. [8]
(n = 166: 66 M, 100 F;
longitudinal study
n = 76: 38 M, 38 F)
le Treated
ohort
 M, 133 F)
FOS Evaluable Treated
Cardiac Cohort




 M, 317 F)
Untreated: Schiffmann et al. [21]
(N = 447: 279 M, 168 F)
ided into an Evaluable Treated cohort and then further subdivided into Evaluable Treated
shaded boxes) from studies by Banikazemi et al. [20], Kampmann et al. [8], and Schiffmann
MI, left ventricular mass indexed to height; M, male.
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findings [23].
Morbidity, as time to and age at first event, was determined using
two clinical composite event endpoints. To compare with untreated
patients from Banikazemi et al. [20], the endpoint comprised myocardi-
al infarction, any serious cardiac event indicative of coronary artery dis-
ease, heart failure, valvular disease, or arrhythmia; any event resulting
in or reported as percutaneous transluminal coronary angioplasty or
coronary artery bypass graft; any serious heart failure event; serious
events requiring valvular surgery; serious adverse events stating or
indicating renal transplant, dialysis, or indicative of chronic dialysis;
an increase in serum creatinine by 33% from baseline (two consecutive
values); cerebrovascular accident, stroke or transient ischemic attack, or
death. The second composite of any myocardial infarction, cardiac sur-
gery, arrhythmia, angina, or heart failure; renal transplant or dialysis,
initiation of renal transplant or dialysis or increase in serum creatinine
by 33% from baseline (two consecutive values); stroke, transient
ischemic attack, or prolonged reversible ischemic neurologic disorder;
and/or death was used for comparison with results by Schiffmann
et al. [21]. Mortality in FOS, evaluated from fatality forms, adverse
events forms, and exit forms, was also compared with the data from
Schiffmann et al. [21].
2.3. Statistical analyses
Progression of renal disease and cardiomyopathy was calculated
from average slopes from mixed models of available eGFR and LVMI
data, using the following equations:
MDRD ¼ Intercept þ α:Ageþ β:Gender þ χ:Baseline MDRDþ δ:Age
 Gender þ η:Age Baseline MDRDþ μ:Gender
 Baseline MDRDþ θ:Age Gender  Baseline MDRDþ ε
ð1Þ
LVMI ¼ Intercept þ α:Ageþ β:Gender þ χ:Baseline LVH þ δ:Age
 Gender þ η:Age Baseline LVH þ μ:Gender  Baseline LVH
þ θ:Age Gender  Baseline LVH þ ε:
ð2Þ
The interaction model procedure PROCMIXED in SAS/STAT® version
9.2 (SAS Institute Inc., Cary, NC, USA)was used to derive eGFR and LVMI
rate of change estimates r. For eGFR evaluations, values after dialysis or
transplantation were removed from the model estimations; serum
creatinine values b0.2 mg/dL or N15 mg/dL were also excluded. For
LVMI analyses, LVMI values b5 g/m2.7 or N1000 g/m2.7 were excluded.
Confidence intervals (CIs) were calculated for FOS data; however,
corresponding CIs were not available for many of the published data.
Kaplan–Meier time to morbidity analyses were conducted for FOS
participants, running from treatment start to the first occurrence of
composite event (for events on or after treatment start only), with cen-
soring for the first of either at last visit or 35 months. Kaplan–Meier
analyses of FOS data were also conducted for age at morbidity, running
from birth to first composite event, and for mortality, with censoring at
last visit (or date of leaving for patients who left FOS to be treated with
another ERT).
2.4. Sensitivity analyses
Each pair of cohorts was compared descriptively to identify
differences in baseline clinical and demographic parameters. Where
such differences were found, confirmatory analysis of randomly
resampled subgroups of the population in question was conducted.
Where significant differences in outcomes were detected in the
study, supportive subgroup analyses were conducted to evaluate
sensitivity and robustness. For cardiac and renal outcomes, analyseswere repeated for treated patients who had available 5-year follow-up
data. An additional sensitivity analysis was done with treated patients
who had renal transplant or dialysis before FOS entry. For mortality, a
supportive analysis for the All Treated cohort was performed, and
results were confirmed by random resampling to match the published
untreated population. For morbidity, supportive analyses for the
endpoints from Schiffmann et al. [21] and Banikazemi et al. [20] were
conducted for the first occurrence of events after adding events from
FOS signs and symptoms forms that had not already been captured as
serious adverse events. The original FOS analysis included patients
with transient ischemic attack, stroke, or myocardial infarction during
the 3 months prior to initiating ERT, whereas such patients were
excluded from the untreated Banikazemi et al. cohort.
3. Results and discussion
At data extraction (November 15, 2012), the FOS All Treated cohort
comprised 740 patients from expert sites in 19 countries. Treated pa-
tient cohorts for analyses were derived from this population (Fig. 1).
We have retrospectively examined long-term changes in renal function,
cardiomyopathy, morbidity, and mortality in patients with Fabry dis-
ease who had been treated with agalsidase alfa and compared these re-
sults with similar cohorts of untreated patients from published studies.
This approachwas taken because an effective comparison of treated and
untreated patients from FOSwas not feasible. As already noted, untreat-
ed patients in FOS tended to have less severe disease; also, less clinical
data have been collected (e.g., safety reporting requirements did not
apply in the same manner to untreated patients [11,14]). Deriving
matched treated and untreated cohorts from FOS would therefore
have generated comparator groups too small to yield valid conclusions.
Two of the untreated cohorts utilized for this study were from natural
history studies [8,21], and the third was the placebo group in a random-
ized trial of agalsidase beta [20]. Data from FOS were extracted to pro-
vide cohorts of treated patients corresponding as closely as possible to
those from the published studies in terms of inclusion/exclusion criteria
and data available.
The FOS Evaluable Treated Renal cohort and corresponding untreat-
ed patients from Schiffmann et al. [21] were broadly comparable in age
and renal function characteristics (Table 1). The FOS Evaluable Cardiac
cohort and the comparator Kampmann et al. [8] cohort were closely
matched in terms of numbers of patients, age, and relevant clinical fac-
tors (Table 2). Of the two untreated cohorts available from the literature
for evaluation of morbidity-related outcomes, the cohort from
Banikazemi et al. [20] comprised mostly males (87% versus 48% in the
FOS Evaluable Morbidity cohort; Table 3). The untreated cohort from
Schiffmann et al. [21] was similar to the gender balance in the matched
FOS cohort (Table 3).
Over a median follow-up of ~5 years (median [range] interval
between first and last eGFR assessment, FOS 5.4 [1.5 to 13.7] years),
the estimated annualized eGFR changewith treatmentwas−2.86 (stan-
dard error of the mean [SEM] 0.53) mL/min/1.73 m2/y among male pa-
tients with poor renal function at baseline (eGFR b60 mL/min/1.73 m2;
Table 4). In patients with higher baseline eGFR (≥60 mL/min/1.73 m2),
the annualized rate of decline in eGFR was less than in patients
with lower baseline eGFR (Table 4). In comparison, the untreated
cohort from Schiffmann et al. [21], with a median (range) follow-
up (interval between first and last eGFR assessment) of 5.6 [0.1 to
28.2] years, had an estimated annualized eGFR change of −6.8
(SEM 1.5) mL/min/1.73 m2/y. When comparing the FOS Evaluable
Treated Renal cohort and the Schiffmann et al. untreated cohort, the ef-
fect of ERT on annualized eGFR change was seen across all baseline uri-
nary protein level categories (Table 4). In a sensitivity analysis, eGFR
results were evaluated only for FOS ERT patients who had 5-year data
(79 males, 71 females; median [range] treatment duration, 8.25 [2.7
to 13.8] years). The annualized eGFR slopes for these patients, overall
and grouped by baseline eGFR, were not significantly different from
Table 1
Baseline renal function–related clinical characteristics of patients from FOS and Schiffmann et al. [21] who were included in the analyses of the progression of renal impairment.
By baseline eGFR (mL/min/1.73 m2)
Parameter (mean at baseline) FOS Evaluable Treated Renal cohort Schiffmann et al. (untreated) [21]
Males (n = 135) Females (n = 133) Males (n = 243) Females (n = 152)
≥60 (n = 117) b60 (n = 18) ≥60 (n = 111) b60 (n = 22) ≥60 (n = 189) b60 (n = 54) ≥60 (n = 129) b60 (n = 23)
Age (yrs) 34.7 44.1 44.1 55.8 27.3 41.8 38.0 51.9
Urinary protein (g/24 h) 0.4 1.5 0.5 1.0 0.6 2.6 0.3 1.1
Overt proteinuria (%) 40 93 37 56 37 96 20 50
Systolic BP (mm Hg) 124 124 126 133 125 128 123 135
Diastolic BP (mm Hg) 73 77 74 76 74 79 75 82
By baseline urinary protein (g/24 h)
Parameter
(mean at baseline)
FOS Evaluable Treated Renal cohort Schiffmann et al. (untreated) [21]

























Age (yrs) 38.8 36.1 37.0 46.9 45.7 42.1 38.9 36.0 22.8 47.2 42.3 39.0
eGFR (mL/min/1.73 m2) 74.4 101.8 105.0 65.7 87.3 80.2 58.5 84.6 138.0 63.4 89.6 91.9
BP, blood pressure; eGFR, estimated glomerular filtration rate; FOS, Fabry Outcome Survey.
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ity analysis looked at eGFR results when patients on dialysis or those
that had received a renal transplant before FOS entry were included in
the FOS Evaluable Treated Renal cohort (Supplemental Tables 1 and 2).
A number of patients in each cohort had been treated with
angiotensin-converting enzyme inhibitors (ACEI) or angiotensin recep-
tor blockers (ARB), which is a potential source of bias. In the untreated
cohort, 20% (n=48) ofmales and 12% (n=18) of females had received
ACEI [21], compared with 57% (n = 77) of males and 65% (n = 87) of
females in the FOS Evaluable Treated Renal cohort who had received ei-
ther ACEI or ARB at some time during the periods analyzed. In treated
patients, the annualized slopes of eGFR were not significantly different
between patients who had or had not received an ACEI or ARB (−1.37
[SEM 0.22; 95% CI −1.81, −0.94; n = 164] mL/min/1.73 m2/y and
−1.48 [SEM 0.84; 95% CI−3.15, 0.19; n = 104], respectively).
Overall, patients treatedwith agalsidase alfa had a negligible annual-
ized rate of change in LVMI (median [range] follow-up, 5.2 [1.5 to 11.4]
years; Table 5). The mean (SEM) rate of LVMI change was 0.33 (0.10)
g/m2.7/y in males and 0.48 (0.09) in females, comparedwith LVMI in-
creasing at a rate of 4.07 (1.03) in untreated males and 2.31 (0.81) in
untreated females. In males and females with left ventricular hyper-
trophy (LVH) at baseline, the differences in the rate of change
between the ERT and untreated cohorts were suggestive of a treat-
ment effect, although the SEMs for the untreated cohort values
were high (Table 5). Six patients (all males, five with baseline LVH)
were originally excluded from the FOS cohort because of prior
renal dialysis and/or transplant; inclusion of these patients in the
LVMI analysis had no significant impact on the findings (Supplemen-
tal Table 3).
A sensitivity analysis evaluating available 5-year follow-up LVMI
data was conducted in 38 males and 40 females (median [range]
treatment duration, 8.45 [0.9 to 11.7] years). In both, the rates of changeTable 2
Ages and cardiovascular-related clinical characteristics at baseline of patients from FOS and Ka
FOS Evaluable Treated Cardiac cohort (n =
Parameter (means) Males (n = 71) Females
Age at baseline LVMI (yrs) 31.3 41.9
BMI (kg/m2) 21.9 24.4
LVMI (g/m2.7) 53.9 51.0
Systolic BP (mm Hg) 124.7 124.3
Diastolic BP (mm Hg) 73.4 70.5
Heart rate (beats/min) 71.8 69.0
BMI, body mass index; BP, blood pressure; FOS, Fabry Outcome Survey; LVMI, left ventricular min LVMI overall and in patients with baseline LVHwere not significantly
different from the corresponding values for the full FOS ERT cardiac
cohort (Supplemental Table 4).
Treatment appeared to delay morbidity in patients with Fabry dis-
ease. After 24 months, the probability of a composite morbidity event
was ~16% (standard error [SE] 4.7%) in the FOS ERT cohort overall com-
pared with ~45% overall for the Banikazemi et al. [20] placebo group
(Fig. 2a). Because the majority of patients (87%) in the Banikazemi
et al. placebo group were male, it is logical to compare the probability
with that of the subset of male patients in the FOS Evaluable Treated
Morbidity cohort, which was ~26% (SE 8.8%). Given the more progres-
sive nature of the disease in males, examining males only represents
the worst case clinical scenario. Median (95% CI) age at first event was
also greater in agalsidase alfa–treated males and females, respectively,
at 48 (44.2, 50.4) years and 56.9 (54.1, 59.9) years compared with un-
treated patients, at ~41 years and ~53 years, respectively (Fig. 2b).
Treatment with agalsidase alfa also appeared to have a positive ef-
fect on mortality. The estimated median survival time was 77.5 years
for male patients from FOS compared with 60 years in patients without
ERT [21] (Fig. 3). Sensitivity analyses excluding patients from FOS who
initiated treatment later in life (i.e., aged ≥65 years) or using random re-
sampling of replicates to match the untreated population demographic
yielded a median estimated 50% risk of mortality at age ≥70 years.
Over ~5 years, treatment with agalsidase alfa slowed the progres-
sion of renal disease, particularly in males and in those with lower
eGFR at baseline. Agalsidase alfa appeared to slow or stabilize progres-
sion of cardiomyopathy, including patients with LVH at baseline. Risk
of morbidity was also reduced in treated patients from FOS and survival
was improved. Our findings of beneficial effects of agalsidase alfa on the
progression of renal impairment and cardiomyopathy outcomes concur
broadly with those from previous analyses of treated patients from FOS
and from other studies [11,13,15–17,24–26]. In treated patients frommpmann et al. [8] included in the analyses of the progression of cardiomyopathy.
164) Kampmann et al. [8] (untreated) (n = 166)







ass indexed to height.
Table 3
Two comparator patient cohorts (Banikazemi et al. [20] and Schiffmann et al. [21]) were
utilized to evaluate morbidity and mortality outcomes for treated patients in two
comparable FOS cohorts.
Parameter (mean) FOS Evaluable Treated
Morbidity cohort
Banikazemi et al. placebo
group [20]
n 79 31
Males (%) 48 87
Age at treatment start (yrs) 51.6 44.3
Weight (kg) 71.4 70.2
Height (cm) 167.3 172.8
White, Asian (%) 80, 18 87, 3
Urine protein (g/24 h) 0.6 1.1
Albumin/creatinine ratio (mg/g)a 910 900
Plasma creatinine (mg/dL) 1.2 1.6
eGFR (mL/min/1.73 m2) 63.9 52.4
Systolic BP (mm Hg) 127 128





Males Females Total Males Females Total
n 360 317 677 279 168 447
Age at data abstraction (yrs) 40.8 50.6 45.4 38.6 44.9 41.0
Age at first symptom (yrs) 14.3 24.9 19.0 10.5 17.4 12.6
Age at diagnosis (yrs) 27.1 39.1 32.7 23.9 29.7 26.0
White (%) 82 84 83 85 86 85
BP, blood pressure; eGFR, estimated glomerular filtration rate; FOS, Fabry Outcome
Survey.
a This represents the ratio of albumin (mg/dL) to creatinine (g/dL) in urine.
Table 5
Progression of cardiomyopathy, determined as annualized rate of change in LVMI, inmale





Mean annualized LVMI slope (SEM) [95% CI],a g/m2.7/y
Baseline LVH status n n
Males
Total 71 0.33 (0.10)
[0.13, 0.53]
39 4.07 (1.03)
LVH 29 0.19 (0.16)
[−0.13, 0.50]
18 6.59 (8.5)




Total 93 0.48 (0.09)
[0.30, 0.66]
39 2.31 (0.81)
LVH 45 0.77 (0.14)
[0.49, 1.05]
15 3.77 (7.7)
No LVH 48 0.19 (0.11)
[−0.03, 0.41]
Not availableb
CI, confidence interval; FOS, Fabry Outcome Survey; LVH, left ventricular hypertrophy;
LVMI, left ventricular mass indexed to height; SEM, standard error of the mean.
a Median (range) follow-up period: FOS, 5.2 (1.5 to 11.4) years; Kampmann et al., 4.5
(1.1 to 9.0) years [8].
b 95% CI for LVMI data were not published by Schiffmann et al. [21].
25M. Beck et al. / Molecular Genetics and Metabolism Reports 3 (2015) 21–27the FOS with a mean follow-up period of 7.4 years, progression of renal
impairment was stabilized in women and showed a small decline in
men [16]. Furthermore, FOS 5-year data indicated a sustained reductionTable 4
Progression of renal impairment determined as annualized rate of change in eGFR inmale





Mean annualized eGFR slope (SEM) [95% CI],a mL/min/1.73 m2/y
Subgroup n n
Baseline eGFR category (mL/min/1.73 m2)
Males
≥60 117 −1.68 (0.19)
[−2.05, −1.31]
117 −3.0 (0.1)




≥60 111 −0.43 (0.21)
[−0.83, −0.02]
42 −0.9 (0.9)
b60 22 0.36 (0.42)
[−0.47, 1.19]
13 −2.1 (1.6)
Baseline urinary protein level category (g/24 h)
Males
≥1.0 16 −4.76 (0.56)
[−5.85, −3.66]
22 −6.9 (1.5)
0.1 to 1.0 74 −1.62 (0.23)
[−2.08, −1.17]
21 −3.3 (1.8)




≥1.0 17 −0.41 (0.51)
[−1.42, 0.59]
5 −4.6 (2.3)
0.1 to 1.0 70 −0.44 (0.26)
[−0.95, 0.07]
17 −2.2 (2.2)
b0.1 22 −0.16 (0.42)
[−0.97, 0.66]
7 −0.6 (2.6)
CI, confidence interval; eGFR, estimated glomerular filtration rate; FOS, Fabry Outcome
Survey; SEM, standard error of the mean.
a Median (range) number of assessments for males and females: Schiffmann et al.,
6 (3 to 33); FOS, 10 (3 to 70).in LVMI in treated patientswith baseline cardiac hypertrophy and stable
LVMI in treated patients without baseline hypertrophy [11]. A random-
ized, double-blind clinical trial showed a significant reduction in left
ventricular mass following 6 months of agalsidase alfa treatment
compared with placebo [13]. One study of patients treated with either
agalsidase alfa or beta for ~5 years suggests that the risk of a first or sec-
ond renal, cardiac, or cerebrovascular event decreased with increasing
treatment duration [27]. A recent cohort study of adults in England by
Anderson et al. found that time on agalsidase alfa or agalsidase beta
ERT was significantly associated with a reduction in LVMI as well as
reduced risk of proteinuria and, among those without baseline protein-
uria, a small increase in eGFR [28]. Another recent study by Juan et al. of
six patients in Argentina with mild disease at baseline found that after
10 years of agalsidase beta ERT, no patients had a reduction in eGFR or
progression to LVH [29]. Results of other studies suggest that long-term
agalsidase beta delays the time to morbidity and death [10,20], although
another study suggested no difference in event rate in patients with ad-
vanced disease at baseline versus an untreated control group [30].
The main strengths of our study are the inclusion of robust compar-
ator datasets and the availability of data for N700 treated patients.
Limitations include the fact that this was a retrospective analysis, not
a randomized controlled clinical trial and, as discussed above, compari-
sons were not made with untreated patients from the same dataset.
Matching at the patient level was not possible, as individual patient
data for the untreated comparators was not available. Lack of randomi-
zation introduces the risk of bias in terms of treatment selection and as-
certainment, with the possibility of more severely affected patients
beingmore likely to be selected for ERT, to have more clinical attention,
or to have sentinel events reported. The comparator arms, however,
were the placebo arm from a randomized trial [20] or from retrospec-
tive [21] or cross-sectional [8] studies of untreated patients, some of
whom later received ERT, except for patients from the latter study [8]
who were included in the longitudinal study.
Using comparator groups from published literature presented a
challenge in matching baseline demographic and clinical characteristics
of the treated and untreated patient cohorts, the definitions of certain
endpoints, and study duration and timing. Analysis cohorts from the
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Banikazemi et al. Evaluable Populations (Untreated) [20]
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Fig. 2. Kaplan–Meier survival analyses for morbidity. a. Time to first renal, cardiac or stroke event, or death for agalsidase alfa–treated patients from FOS and untreated (placebo arm) pa-
tients in a study by Banikazemi et al. [20]. b. Age at first event for treated patients from FOS and untreated patients from a study by Schiffmann et al. [21]. BL, baseline; CI, confidence in-
terval; FOS, Fabry Outcome Survey. Right panel of Fig. 2a adapted with permission from Banikazemi et al. [20]. Right panel of Fig. 2b was adapted from Schiffmann et al. [21] with
permission from Oxford University Press. *Cumulative probability function of these events. †Time to first composite event on or after start of agalsidase alfa. ‡Time on study to first com-
posite event. §Age at first composite event on or after start of agalsidase alfa. ∥Age at first composite event.
26 M. Beck et al. / Molecular Genetics and Metabolism Reports 3 (2015) 21–27the published literature. This placed restrictions on which treated pa-
tients from FOS could be included in each comparator cohort. Hence,
for some analyses, these groups were considerably smaller than the
original FOS All Treated cohort. However, the percentage of patients
with eGFR b60 mL/min/1.73 m2 in the FOS Evaluable Treated Renal co-
hort is similar to that of the Schiffmann et al. population (15% versus
21%, respectively) and the percentage of patients with LVH in the FOS
Evaluable Treated Cardiac cohort is similar to that of the Kampmann
et al. population (45% versus 42%, respectively). Additionally, to address
differences in cases where the key baseline parameters of the FOS co-
hort did notmatch those of the published population, resampling simu-
lations matching the baseline parameters were performed as sensitivity
analyses. Another limitation of using data from the published literature
was that further analyses, for example, of interactions between Fabry
disease complications and outcomes, were not possible. Likewise, with
no centralized reading of FOS echocardiograms, LVMI data from two dif-
ferent studies were compared. Patients who left FOS to be treated with
another ERT were censored from the analyses from the date of leaving.
This could be a source of bias because patients likely changed treatment
due to intolerability or perceived lack of benefit; however, the use of
Kaplan–Meier analyses should have reduced any impact of this onmor-
bidity and survival findings. Finally, any long-term study introduces the
potentially unavoidable risk that standards of diagnosis and care might
change over time as well as availability of therapeutic agents, e.g., ACEI
and ARB, a factor that may introduce bias and applied to all cohorts
included in the analysis. Consideration of this risk is important, particu-
larly in relation to the Schiffmann et al. [21] natural history study
retrospective data, which was collected over several decades.4. Conclusions
The findings from this retrospective comparison of data from FOS ver-
sus published studies support the long-term effectiveness of agalsidase
alfa in the treatment of Fabry disease. The results show that treatment
with agalsidase alfa slowed renal deterioration, slowed or stabilized pro-
gression of cardiomyopathy, and appeared to delay morbidity and death.
Interpretation of these findings should take into account that they are
based on retrospective comparisons with previously published data.
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